Recro Pharma (NASDAQ: REPH) and Seattle Genetics (NASDAQ:SGEN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.
Insider and Institutional Ownership
57.9% of Recro Pharma shares are held by institutional investors. Comparatively, 93.1% of Seattle Genetics shares are held by institutional investors. 21.6% of Recro Pharma shares are held by insiders. Comparatively, 34.7% of Seattle Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Recro Pharma and Seattle Genetics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Recro Pharma currently has a consensus target price of $14.42, indicating a potential upside of 33.36%. Seattle Genetics has a consensus target price of $64.40, indicating a potential upside of 26.40%. Given Recro Pharma’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Recro Pharma is more favorable than Seattle Genetics.
Earnings and Valuation
This table compares Recro Pharma and Seattle Genetics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Recro Pharma||$71.83 million||2.88||-$50.08 million||($2.65)||-4.08|
|Seattle Genetics||$482.25 million||16.69||-$125.53 million||($0.88)||-57.90|
Recro Pharma has higher earnings, but lower revenue than Seattle Genetics. Seattle Genetics is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Recro Pharma has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500. Comparatively, Seattle Genetics has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.
This table compares Recro Pharma and Seattle Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Seattle Genetics beats Recro Pharma on 9 of the 14 factors compared between the two stocks.
About Recro Pharma
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
About Seattle Genetics
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company’s pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.